
Oct 24
Instead of limiting @CMSgov's authority to an added safeguard for patients, Congress could instead ensure that the agency has sufficient resources to require RCTs for CED to make known the true benefits & harms of new treatments.
Link to piece: https://t.co/9MQuoHCVqH 9/9

Oct 24

Oct 24
Troublingly, Congress has taken steps to limit @CMSgov's authority by requiring Medicare to automatically cover medical products despite uncertainty at @US_FDA approval such as the MCIT pathway w/in Cures 2.0 for Breakthrough Devices & the #DISARMAct: https://t.co/NY5Z6gcQKo 7/

Oct 24
3⃣ @CMSGov could also encourage private payers who face similar uncertainties around benefits & harms of medical products at the time of @US_FDA approval to also require participation in a robust trial as a condition of coverage https://t.co/2HTqfYkDU7 6/